MSK’s Collaborations Around the World
The vision of Memorial Sloan Kettering Cancer Center (MSK) is to be the world’s leading authority in cancer. To that end, we will continue to pursue partnerships in the US and internationally to collaborate with fellow leaders, advance treatments, and accelerate research breakthroughs. As a global leader in cancer medicine, MSK serves populations near and far and will continue to lead the path towards global health equity. Our mission is ending cancer for life.
Cure4Cancer
MSK and the Asia Society Policy Institute (ASPI) have been working together since 2017 to enhance collaboration between the U.S., China, and the rest of the world in tackling the common enemy of cancer.
This collaborative effort aims to accelerate the eradication of cancer as a major cause of death through multi-stakeholder, multi-regional collaboration on patient-centric clinical trials and international regulatory harmonization. Read about recent activities.
Global Cancer Disparities Initiatives Program
In 2011, MSK launched the Global Cancer Disparities Initiatives (GCDI) program to improve outcomes for people with cancer in low- and middle-income countries, with a focus on sub-Saharan Africa. Learn more.
U.S.-Australia Cancer Consortium
Following President Biden and Prime Minister Albanese’s announcement of U.S.-Australia cooperation in innovative technologies, a U.S.-Australia Cancer Consortium was formed, focusing on pioneering cancer care collaboration. Memorial Sloan Kettering Cancer Center joined the consortium to foster collaboration between the White House Cancer Moonshot, Australia’s NSW Government and other partners to facilitate innovative cancer treatments. Read more.